Histone Deacetylase (HDAC) Assay Service
Creative Biolabs offers a highly sensitive and versatile HDAC Assay Service to support functional analysis, compound screening, and pathway interrogation in immuno-oncology settings. Our platform allows precise measurement of HDAC class I, II, and IV isoforms using enzymatic and cell-based models.
Background
Histone deacetylases (HDACs) are a family of epigenetic enzymes that remove acetyl groups from lysine residues on histone and non-histone proteins, profoundly altering chromatin structure and gene expression. In the context of cancer immunology, HDACs suppress key immune signaling pathways, including MHC class I/II expression, immune checkpoint regulation, cytokine production, and T cell activation. Dysregulated HDAC activity is implicated in immune escape, immune cell exhaustion, and poor antigen presentation in tumors.
Featured Services at Creative Biolabs
We offer HDAC assays tailored for studying immune-associated gene regulation, epigenetic drug discovery, and mechanistic screening:
Fluorometric & Colorimetric HDAC Activity Assays
- Utilize acetylated lysine substrates with fluorogenic or chromogenic reporters
- Quantify total or isoform-specific HDAC activity in nuclear extracts or recombinant systems
Isoform-Specific Profiling
- Class I (HDAC1, 2, 3, 8), Class II (HDAC4, 5, 6, 7, 9, 10), and Class IV (HDAC11) detection using selective probes and inhibitors
Cell-Based Assays for Acetylation Status
- Measurement of intracellular histone acetylation via ELISA or immunoblot following HDAC inhibition
- Readouts of downstream immune activation markers (e.g., HLA-A, PD-L1, IFN-γ expression)
Immune-Tumor Interaction Models
- Co-culture systems to monitor HDAC effects on antigen presentation, cytokine release, and T cell reactivity
High-Throughput Capability
Scalable formats for screening HDAC inhibitors with Z' > 0.8 and robust assay performance metrics
Workflow
Highlights
- Immuno-Oncology Focus – Tailored assays for HDAC roles in immune evasion, cytokine silencing, and antigen presentation
- Isoform Resolution – Discrimination of individual HDAC family members using class-specific inhibitors and probes
- Multiplex Capabilities – Combine HDAC activity with immune marker readouts in co-culture or reporter models
- High Sensitivity – Detect HDAC activity in low-abundance immune subsets (e.g., TILs, dendritic cells)
- HTS Ready – Miniaturized platforms with robust reproducibility for epigenetic drug screening pipelines
FAQs
Q1: Can you differentiate between HDAC classes or isoforms?
A1: Yes. We offer isoform-specific detection using selective inhibitors, substrates, or antibody-based readouts for class I, II, and IV HDACs.
Q2: How do you assess downstream immunological effects of HDAC inhibition?
A2: We analyze changes in MHC I/II expression, checkpoint molecule transcription, and cytokine levels using flow cytometry, qPCR, and ELISA following HDAC inhibition in immune cells or tumor models.
Q3: Is this service suitable for testing HDAC inhibitors?
A3: Absolutely. We provide dose–response profiling, IC₅₀ determination, and mechanism-of-action studies for HDAC-targeted compounds.
Q4: Do you support epigenetic modulation in T cell exhaustion or macrophage polarization?
A4: Yes. We can test HDAC inhibitor effects in specific immune contexts such as exhausted CD8⁺ T cells or M1/M2 macrophage models.
Q5: Can you run HDAC assays using primary human immune cells?
A5: Yes, we support both primary PBMC-derived subsets and established immune cell lines for HDAC profiling.
Partner with Us to Advance HDAC-Targeted Immunoepigenetic Research
Creative Biolabs provides advanced HDAC profiling solutions to support your immuno-oncology discovery programs. Whether you're exploring epigenetic reprogramming, immune enhancement, or HDAC-targeted drug candidates, our expert team offers full technical support and customized workflows.
Download our brochure